Litcius/Paper detail

Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2

Benjamin Israelow, Tianyang Mao, Jon Klein, Eric Song, Bridget L. Menasché, Saad B. Omer, Akiko Iwasaki

2021Science Immunology201 citationsDOIOpen Access PDF

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 160 million infections and more than 3 million deaths worldwide. Although effective vaccines are currently being deployed, the adaptive immune determinants that promote viral clearance and confer protection remain poorly defined. Using mouse models of SARS-CoV-2, we demonstrate that both humoral and cellular adaptive immunity contribute to viral clearance in the setting of primary infection. Furthermore, we find that either convalescent mice or mice that receive mRNA vaccination are protected from both homologous infection and infection with a variant of concern, B.1.351. In addition, we find that this protection is largely mediated by antibody response and not cellular immunity. These results highlight the in vivo protective capacity of antibodies generated to both vaccine and natural infection.

Topics & Concepts

VirologyImmunityImmune systemVaccinationAntibodyAcquired immune systemBiologyImmunologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immune escapeCoronavirus disease 2019 (COVID-19)Antibody response2019-20 coronavirus outbreakMedicineDiseaseInfectious disease (medical specialty)OutbreakPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2 | Litcius